Alteogen announced on the 23rd that it will present research results regarding subcutaneous (SC) dosing for antibody-drug conjugate (ADC) therapies at the 'World ADC Asia 2026' conference. The event is scheduled to take place in Seoul from June 9 to 11.
While ADCs are recognized for their potent anticancer effects, their highly toxic payloads can frequently cause systemic side effects. In clinical practice, this often makes it challenging to establish a dosage that balances therapeutic efficacy with patient safety.
Through internal research, Alteogen has confirmed that utilizing its proprietary recombinant human hyaluronidase, ALT-B4, to convert intravenous ADC therapies into subcutaneous injections can improve safety profiles by modulating drug concentrations in the blood.
When administered intravenously, the infusion rate of an ADC must often be strictly controlled to prevent dangerously high peak blood concentrations. In contrast, a subcutaneous formulation enabled by ALT-B4 allows for more convenient and rapid administration. Because SC delivery causes blood concentrations to rise more gradually, it is expected to mitigate the side effects typically associated with the toxic payload.
"Alteogen is researching more efficient and improved delivery methods for ADC therapies using ALT-B4," said Dr. Soon-jae Park, CEO of Alteogen. "We believe subcutaneous formulations will represent a paradigm shift in how ADCs are administered."
